Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
1.570
0.00 (0.00%)
At close: Jan 23, 2026, 4:00 PM EST
1.545
-0.025 (-1.58%)
After-hours: Jan 23, 2026, 7:43 PM EST
Jasper Therapeutics Employees
Jasper Therapeutics had 27 employees as of September 30, 2025. The number of employees decreased by 37 or -57.81% compared to the same quarter last year.
Employees
27
Change
-37
Growth
-57.81%
Revenue / Employee
n/a
Profits / Employee
-$3,371,148
Market Cap
43.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 27 | -37 | -57.81% |
| Dec 31, 2024 | 64 | 19 | 42.22% |
| Dec 31, 2023 | 45 | 10 | 28.57% |
| Dec 31, 2022 | 35 | 10 | 40.00% |
| Sep 30, 2022 | 36 | 14 | 63.64% |
| Jun 30, 2022 | 35 | 11 | 45.83% |
| Mar 31, 2022 | 34 | 12 | 54.55% |
| Dec 31, 2021 | 25 | 3 | 13.64% |
| Sep 30, 2021 | 22 | - | - |
| Jun 30, 2021 | 24 | - | - |
| Mar 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 64 |
| Kezar Life Sciences | 55 |
| OnKure Therapeutics | 46 |
| NextCure | 43 |
| Actinium Pharmaceuticals | 37 |
| INmune Bio | 22 |
| Veru Inc. | 20 |
| TuHURA Biosciences | 19 |
JSPR News
- 17 days ago - Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript - Seeking Alpha
- 17 days ago - Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - GlobeNewsWire
- 17 days ago - Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - GlobeNewsWire
- 7 weeks ago - Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript - Seeking Alpha
- 7 weeks ago - Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - GlobeNewsWire
- 7 weeks ago - Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - GlobeNewsWire
- 2 months ago - Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 2 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - Newsfile Corp